INVO FERTILITY INC (IVF)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$0.96-2.26%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Sustain revenue growth through acquisitions and organic expansion: FY26 revenue guidance $4.2M vs $10.4M target.
INVO Fertility grew revenue 23% year-over-year to $2.02M in 2026-Q1. Operating losses improved from -$2.99M in 2025-Q2 to -$1.59M in 2026-Q1. The company is expanding through acquisitions and forming partnerships. These moves could stabilize and grow the business.
The company is still loss-making with EPS expected at -$23.2M in 2026. It faces Nasdaq delisting risks due to regulatory issues. Revenue growth and profit improvements may stall or reverse, risking further share price declines.
The market prices in about 74% revenue growth next year, reflecting optimism on expansion. Our fair value at $12.32 suggests the stock is cheap versus peers, but risks remain from regulatory and profitability challenges.
Breaks if: operating loss worsens beyond -$1.59M in next 4 quarters
Breaks if: Nasdaq delisting occurs or new regulatory penalties arise
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown volatility in management and financial performance, which adds to the uncertainty of its long-term prospects.
The market seems to have priced in a low level of fragility, indicating that investors are not overly concerned about immediate risks. However, the valuation is considered cheap compared to peers, suggesting that expectations for future performance may be lower than what is needed for significant growth.
Management is focused on driving organic growth and improving profitability through clinic expansion. However, there is a high near-term risk of an earnings miss, which could negatively impact investor sentiment and performance.
The future performance of IVF will depend on its ability to meet or exceed earnings expectations, as well as broader market conditions, particularly in the healthcare sector. Key triggers include guidance changes and the performance of sector peers.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped to the bottom half of its sector. This change means the reason to own it has weakened. The company improved operating income and adjusted EBITDA. However, revenue fell short of estimates, which challenges this improvement.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $10.4M in FY26
Pursue disciplined acquisitions of established fertility clinics to add scale, expand geographic footprint, and enhance long-term earnings power.
In the next 1 to 3 years, IVF's success will largely depend on management execution and external market factors. Not investment advice.